Who is sponsoring NCT06082934?

NCT06082934 is sponsored by Xijing Hospital.

What condition does NCT06082934 study?

NCT06082934 studies Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia.

Is NCT06082934 still recruiting?

NCT06082934 is currently recruiting now. Last updated 13 October 2023.

Last reviewed 2023-10-13 · How we verify

NCT06082934

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Recruiting now Phase 1, PHASE2 Last updated 13 October 2023

What this trial tests

Phase 1, PHASE2 trial testing Olverembatinib plus venetoclax and dexamethasone in Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia in 30 participants. Currently enrolling.

Timeline

1 November 2023

Primary endpoint
1 November 2026

1 November 2026

Quick facts

Lead sponsor	Xijing Hospital
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 November 2023
Primary completion	1 November 2026
Estimated completion	1 November 2026
Sites	1 location across China

Drugs / interventions tested

Olverembatinib plus venetoclax and dexamethasone — full drug profile →

Conditions studied

Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia — all drugs for Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia →

Sponsor

Xijing Hospital

Who can join

18 and older, any sex, with Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

B-Cell Lymphoma 2 Inhibition in Acute Lymphoblastic Leukemia: Mechanisms, Resistance, and Emerging Combinations With Venetoclax.
Hanbali A, Kotb A, Saleh M. · · 2025 · cited 1× · PMID 40904937 · DOI 10.14740/jh2092
One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors.
Dozandeh-Jouybari A, Rohaninia E, Faaliat S, Joudaki N, et al · · 2025 · cited 1× · PMID 40624659 · DOI 10.1186/s12935-025-03869-w
Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies-a comprehensive review of clinical outcomes.
Sadati S, Yazdizadeh S, Razavi SM, Homayoonfal M, et al · · 2026 · PMID 41547674 · DOI 10.1007/s12672-026-04438-x
The use of venetoclax in the treatment of acute lymphoblastic leukemia-a systematic review.
Kowalczyk A, Zarychta J, Zawitkowska J, Lejman M. · · 2026 · PMID 41523908 · DOI 10.1177/17588359251403912

Verify or expand the search:

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06082934 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 13 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06082934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing